KR102720550B1 - 4-아자인돌 화합물 - Google Patents

4-아자인돌 화합물 Download PDF

Info

Publication number
KR102720550B1
KR102720550B1 KR1020207020519A KR20207020519A KR102720550B1 KR 102720550 B1 KR102720550 B1 KR 102720550B1 KR 1020207020519 A KR1020207020519 A KR 1020207020519A KR 20207020519 A KR20207020519 A KR 20207020519A KR 102720550 B1 KR102720550 B1 KR 102720550B1
Authority
KR
South Korea
Prior art keywords
pyridin
pyrrolo
triazolo
isopropyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207020519A
Other languages
English (en)
Korean (ko)
Other versions
KR20200100709A (ko
Inventor
알라릭 제이. 딕맨
담펄 에스. 도드
크리스토퍼 피. 무사리
트레버 씨. 셔우드
브라이언 케이. 위틀리
존 엘. 길모어
스리칸타 라트나 쿠마르
락스만 파수누리
피타니 비라 벤카타 스리니바스
스리니바산 쿤치타파탐 두라이사미
수브라마냐 헥드
루시트 쿠마르 아누물라
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20200100709A publication Critical patent/KR20200100709A/ko
Application granted granted Critical
Publication of KR102720550B1 publication Critical patent/KR102720550B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020207020519A 2017-12-18 2018-12-17 4-아자인돌 화합물 Active KR102720550B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599875P 2017-12-18 2017-12-18
US62/599,875 2017-12-18
PCT/US2018/065908 WO2019125977A1 (en) 2017-12-18 2018-12-17 4-azaindole compounds

Publications (2)

Publication Number Publication Date
KR20200100709A KR20200100709A (ko) 2020-08-26
KR102720550B1 true KR102720550B1 (ko) 2024-10-21

Family

ID=65003548

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020519A Active KR102720550B1 (ko) 2017-12-18 2018-12-17 4-아자인돌 화합물

Country Status (28)

Country Link
US (4) US10544143B2 (https=)
EP (1) EP3728252B1 (https=)
JP (1) JP7289301B2 (https=)
KR (1) KR102720550B1 (https=)
CN (1) CN111819176B (https=)
AR (1) AR113959A1 (https=)
AU (1) AU2018388464B2 (https=)
BR (1) BR112020011771A2 (https=)
CA (1) CA3085817A1 (https=)
CL (1) CL2020001546A1 (https=)
DK (1) DK3728252T3 (https=)
EA (1) EA202091484A1 (https=)
ES (1) ES2960411T3 (https=)
FI (1) FI3728252T3 (https=)
HR (1) HRP20231244T1 (https=)
HU (1) HUE064473T2 (https=)
IL (1) IL275344B2 (https=)
LT (1) LT3728252T (https=)
MX (1) MX2020006168A (https=)
PE (1) PE20210129A1 (https=)
PL (1) PL3728252T3 (https=)
PT (1) PT3728252T (https=)
RS (1) RS64728B1 (https=)
SG (1) SG11202005628RA (https=)
SI (1) SI3728252T1 (https=)
SM (1) SMT202300342T1 (https=)
TW (1) TWI689510B (https=)
WO (1) WO2019125977A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EA202091484A1 (ru) * 2017-12-18 2021-03-25 Бристол-Маерс Сквибб Компани 4-азаиндольные соединения
KR102730859B1 (ko) * 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
SG11202005733QA (en) * 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
EP3728218B1 (en) * 2017-12-20 2021-12-01 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
EP3802539B1 (en) 2018-06-05 2023-09-20 F. Hoffmann-La Roche AG Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
EP3807270B1 (en) 2018-06-12 2023-09-13 F. Hoffmann-La Roche AG Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
CN112584903B (zh) 2018-07-23 2025-12-23 豪夫迈·罗氏有限公司 用于自身免疫性疾病治疗的哌嗪化合物
EP3847169A1 (en) 2018-09-04 2021-07-14 F. Hoffmann-La Roche AG Benzothiazole compounds for the treatment of autoimmune diseases
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
EP3847173B1 (en) 2018-09-06 2023-04-12 F. Hoffmann-La Roche AG Novel pyrazolopyridine compounds for the treatment of autoimmune disease
EP4041730A1 (en) * 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
WO2021084022A1 (en) 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
EP4051388A1 (en) * 2019-11-01 2022-09-07 Bristol-Myers Squibb Company Substituted pyrazole compounds as toll receptor inhibitors
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
WO2021099406A1 (en) 2019-11-20 2021-05-27 F. Hoffmann-La Roche Ag Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
CN116075510A (zh) 2020-08-19 2023-05-05 百时美施贵宝公司 1H-苯并[d]咪唑衍生物作为TLR9抑制剂用于治疗纤维化
WO2022040293A1 (en) * 2020-08-19 2022-02-24 Bristol-Myers Squibb Company Substituted heteroaryl compounds useful as inhibitors of tlr9
AU2021328575A1 (en) * 2020-08-19 2023-03-16 Bristol-Myers Squibb Company Imidazo(1,2-a)pyridine and (1,2,4)triazolo(1,5-a)pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis
WO2022040267A1 (en) 2020-08-19 2022-02-24 Bristol-Myers Squibb Company 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
AU2021385752A1 (en) * 2020-11-26 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused tricyclic compound, preparation method therefor and application thereof in medicine
CN116783202A (zh) * 2021-02-09 2023-09-19 吉利德科学公司 噻吩并吡咯化合物
CR20230478A (es) 2021-04-16 2023-11-30 Gilead Sciences Inc Compuestos de tienopirrol.
KR20240056747A (ko) 2021-09-10 2024-04-30 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
CN114591339B (zh) * 2022-05-10 2022-08-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
AU2024249981A1 (en) 2023-04-06 2025-10-16 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221213T3 (es) 1997-10-20 2004-12-16 F. Hoffmann-La Roche Ag Inhibidores de kinasa biciclicos.
WO2000035886A2 (en) 1998-12-18 2000-06-22 Axys Pharmaceuticals, Inc. (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
US7427682B2 (en) 2004-05-03 2008-09-23 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
CA2648652A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
JP2010511018A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物
GB0708141D0 (en) 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
CL2009000904A1 (es) * 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
JP5788316B2 (ja) * 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
WO2010036905A1 (en) 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Benzoxazole compounds and methods of use
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
ES2467108T3 (es) * 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JP5864417B2 (ja) 2009-07-16 2016-02-17 マリンクロッド エルエルシー トール様受容体９のアンタゴニストとしての（＋）−モルフィナンおよびその治療的使用
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
CN103562201B (zh) 2011-01-12 2016-10-19 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
DK2663550T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
KR102052215B1 (ko) 2011-06-01 2019-12-04 야누스 바이오테라퓨틱스, 인크. 신규한 면역 시스템 조절제
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
KR101913135B1 (ko) 2011-07-15 2018-10-30 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
JP2013075834A (ja) 2011-09-29 2013-04-25 Kowa Co Ｔｌｒ９阻害活性を有するピラゾロピリミジン−７−アミン誘導体
WO2013052550A2 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
TWI619704B (zh) 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 羧酸化合物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
JP6223563B2 (ja) 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
CN105992766A (zh) 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
EP3398948A3 (en) 2014-08-22 2018-12-05 Janus Biotherapeutics, Inc. 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
BR112019001270A2 (pt) * 2016-07-30 2019-04-30 Bristol-Myers Squibb Company compostos indol substituídos com dimetoxifenila como inibidores de tlr7, tlr8 ou tlr9
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
EA202091484A1 (ru) * 2017-12-18 2021-03-25 Бристол-Маерс Сквибб Компани 4-азаиндольные соединения

Also Published As

Publication number Publication date
US20190185469A1 (en) 2019-06-20
FI3728252T3 (fi) 2023-10-18
EP3728252A1 (en) 2020-10-28
SMT202300342T1 (it) 2023-11-13
US11820768B2 (en) 2023-11-21
EA202091484A1 (ru) 2021-03-25
AR113959A1 (es) 2020-07-01
IL275344B2 (en) 2023-08-01
HUE064473T2 (hu) 2024-03-28
US10730877B2 (en) 2020-08-04
BR112020011771A2 (pt) 2020-11-17
CA3085817A1 (en) 2019-06-27
JP7289301B2 (ja) 2023-06-09
US20220340555A1 (en) 2022-10-27
CL2020001546A1 (es) 2020-10-23
LT3728252T (lt) 2023-10-25
IL275344A (en) 2020-07-30
SI3728252T1 (sl) 2023-11-30
MX2020006168A (es) 2020-08-13
US10544143B2 (en) 2020-01-28
US20200095247A1 (en) 2020-03-26
JP2021506858A (ja) 2021-02-22
KR20200100709A (ko) 2020-08-26
AU2018388464A1 (en) 2020-07-30
RS64728B1 (sr) 2023-11-30
ES2960411T3 (es) 2024-03-04
EP3728252B1 (en) 2023-08-09
PT3728252T (pt) 2023-10-26
PE20210129A1 (es) 2021-01-19
SG11202005628RA (en) 2020-07-29
CN111819176A (zh) 2020-10-23
HRP20231244T1 (hr) 2024-02-16
WO2019125977A1 (en) 2019-06-27
IL275344B1 (en) 2023-04-01
TW201927780A (zh) 2019-07-16
PL3728252T3 (pl) 2023-10-23
DK3728252T3 (da) 2023-11-13
US11053244B1 (en) 2021-07-06
AU2018388464B2 (en) 2022-07-21
TWI689510B (zh) 2020-04-01
CN111819176B (zh) 2023-12-15

Similar Documents

Publication Publication Date Title
KR102720550B1 (ko) 4-아자인돌 화합물
US11912703B2 (en) 6-azaindole compounds
KR102742178B1 (ko) Tlr 억제제로서 유용한 치환된 인돌 화합물
KR102755258B1 (ko) Tlr 억제제로서 유용한 아미드 치환된 인돌 화합물
KR102722182B1 (ko) 디아자인돌 화합물
KR102781141B1 (ko) 치환된 인돌 에테르 화합물
WO2019028301A1 (en) INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL
US20230117470A1 (en) Substituted pyrazole compounds as toll receptor inhibitors
EA041852B1 (ru) 4-азаиндольные соединения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200715

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211217

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240129

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241007

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241017

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241017

End annual number: 3

Start annual number: 1

PG1601 Publication of registration